NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chief Financial Officer Jack McGovern is scheduled to present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, 2017, at 2:10 p.m. Eastern time (11:10 a.m. Pacific time). The conference is being held at the New York Palace Hotel in New York City.

A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.

About Avenova®

Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay's progress:

Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005199/en/

NovaBay ContactsFor NovaBay Avenova purchasing information, please contact:Email usCall us: 1-800-890-0329www.Avenova.comorFrom the CompanyJack McGovernChief Financial Officer510-899-8800jmcgovern@novabay.comorInvestor Contact:LHA Investor RelationsJody Cain310-691-7100Jcain@lhai.com

NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024